SHOCK-VECTOR

A randomized controlled trial of anterior-posterior versus anterior-lateral shock vectors for electrical cardioversion of atrial fibrillation

Objective

SHOCK-VECTOR is an investigator-initiated parallel-group randomized controlled trial investigating the efficacy of anterolateral (AL) vs anteroposterior (AP) electrode placement for electrical cardioversion of AF. SHOCK-VECTOR includes a partial factorial randomized sub-study of manual pressure versus none in patients who are refractory to an initial maximal energy (200J) shock. This trial will be the first adequately powered trial to answer these questions, and if positive, will change practice internationally.

  1. Inclusion

    • Consenting adult (>18 years old) patients scheduled for non-emergent electrical cardioversion of AF will be considered

  2. Exclusion

    • Contraindication to electrical cardioversion as per Canadian Cardiovascular Society guidelines, most commonly:
      • Inadequate anticoagulation
      • Left atrial thrombus not ruled out by transesophageal echocardiography
    • Condition prohibiting AL or AP placement or use of manual pressure (e.g. active skin rash or infection, chest wall deformity, subcutaneous implantable cardioverter defibrillator
Not enrolling

Additional Info

Ethics ID: REB26-0281

ClinicalTrials.gov ID: NCT05511389

 

Sponsor: McMaster University

 

PI: Dr. Derek Chew

 

Admin: Nirav Bhagat

Phone: 403 210 3996

Email: nirav.bhagat1@ucalgary.ca